Attention Deficit Hyperactivity Disorder Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-05　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 26,557 Mn
2033 年預估規模: USD 42,943 Mn
年複合成長率 CAGR: 7.1%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-05頁數 152報告編號 CMI830

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate), Non-stimulants (Atomoxetine, Bupropion, Guanfacine, Clonidine)), By Age Group (Pediatric and Adolescent, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

報告摘要

The global attention deficit hyperactivity disorder (ADHD) treatment market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, and combined presentation. Various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight. It is a chronic condition which affects millions of children and often continue until the adulthood. Children with attention deficit hyperactivity disorder often suffer and struggle with low self-esteem and poor performance in school. Attention deficit hyperactivity disorder are not curable but can deal with symptoms. Treatment of attention deficit hyperactivity disorder involves medications as well as behavioral intervention. ADHD mainly have symptoms of inattention. ADHD probably results from a combination of factors such as genetics, researchers are looking at possible environmental factors that might raise the risk of developing ADHD and are studying how brain injuries, nutrition, and social environments might play a role in ADHD. Market Dynamics Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) treatment market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is used to treat and to improve attention in children suffering from ADHD. Key features of the study • This report provides an in-depth analysis of the global attention deficit hyperactivity disorder treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global attention deficit hyperactivity disorder treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global attention deficit hyperactivity disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder treatment market Market Segmentation • Drug Type Insights (Revenue, USD Mn, 2026 - 2033) o Stimulants  Amphetamine  Methylphenidate  Dextroamphetamine  Dexmethylphenidate  Lisdexamfetamine Dimesylate o Non-stimulants  Atomoxetine  Bupropion  Guanfacine  Clonidine • Age Group Insights (Revenue, USD Mn, 2026 - 2033) o Pediatric and Adolescent o Adult • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Mn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Amnel Pharmaceuticals LLC. o Eli Lilly And Company o Johnson & Johnson Services, Inc. o Noven Pharmaceuticals, Inc o RespireRx Pharmaceuticals Inc o Otsuka Pharmaceutical Co. Ltd o Neos Therapeutics, Inc. o American Brivision (Holding) Corporation o Novartis AG o Takeda Pharmaceutical Company Limited o GSK plc o Purdue Pharma L.P.Cingulate o Adlon Therapeutics L.P. o Tris Pharma, Inc. o Neuraxpharm o Supernus Pharmaceuticals, Inc. o Aytu Biopharma, Inc

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Drug Type  Market Snapshot, By Age Group  Market Snapshot, By Distribution Channel  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Recent Developments o Acquisitions and Partnerships Scenario o Regulatory Scenario o Pricing Analysis o Brand Mapping o Pipeline Analysis o PEST Analysis 4. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type, 2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Stimulants  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Amphetamine o Methylphenidate o Dextroamphetamine o Dexmethylphenidate o Lisdexamfetamine Dimesylate o Non-Stimulants  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Atomoxetine o Bupropion o Guanfacine o Clonidine 5. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group, 2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Pediatric and Adolescent  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Adult  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 6. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel, 2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Retail Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Online Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 7. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region, 2026-2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Region, 2021 - 2033 o North America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)  Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o U.S. o Canada o Latin America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)  Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)  Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)  Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)  Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)  Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o North Africa o Central Africa o South Africa 8. Competitive Landscape o Amnel Pharmaceuticals LLC.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Eli Lilly And Company  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Johnson & Johnson Services, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Noven Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o RespireRx Pharmaceuticals Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Otsuka Pharmaceutical Co., Ltd.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Neos Therapeutics, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o American Brivision (Holding) Corporation  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Takeda Pharmaceutical Company Limited  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o GSK plc  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Purdue Pharma L.P.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Cingulate  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Adlon Therapeutics L.P.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Tris Pharma, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Neuraxpharm  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Supernus Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Aytu Biopharma, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 9. Section o Research Methodology o About Us

提及公司

Amnel Pharmaceuticals LLC.Eli Lilly And CompanyJohnson & Johnson Services, Inc.Noven Pharmaceuticals, IncRespireRx Pharmaceuticals IncOtsuka Pharmaceutical Co. LtdNeos Therapeutics, Inc.American Brivision (Holding) CorporationNovartis AGTakeda Pharmaceutical Company LimitedGSK plcPurdue Pharma L.P.CingulateAdlon Therapeutics L.P.Tris Pharma, Inc.NeuraxpharmSupernus Pharmaceuticals, Inc.Aytu Biopharma, Inc

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們